These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

96 related articles for article (PubMed ID: 3356622)

  • 1. Interactions between antibacterial agents of the quinolone group and nitrofurantoin.
    Shah S; Greenwood D
    J Antimicrob Chemother; 1988 Jan; 21(1):41-8. PubMed ID: 3356622
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The comparative in-vitro activity of eight newer quinolones and nalidixic acid.
    King A; Phillips I
    J Antimicrob Chemother; 1986 Nov; 18 Suppl D():1-20. PubMed ID: 3468100
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In-vitro activity of newer quinolones against aerobic bacteria.
    Auckenthaler R; Michéa-Hamzehpour M; Pechère JC
    J Antimicrob Chemother; 1986 Apr; 17 Suppl B():29-39. PubMed ID: 2940214
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The comparative in-vitro activity of norfloxacin, ciprofloxacin, enoxacin and nalidixic acid against 423 strains of gram-negative rods and staphylococci isolated from infected hospitalised patients.
    Guimaraes MA; Noone P
    J Antimicrob Chemother; 1986 Jan; 17(1):63-7. PubMed ID: 2936708
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In-vitro activity of pefloxacin compared with six other quinolones.
    Ligtvoet EE; Wickerhoff-Minoggio T
    J Antimicrob Chemother; 1985 Oct; 16(4):485-90. PubMed ID: 3864776
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In vitro activity of the newer quinolones compared with the classic ones and tobramycin.
    Boquet Jiménez E; Dalet Escribá F; Caballé L
    Infection; 1985; 13(4):193-6. PubMed ID: 2931382
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [The history of the development and changes of quinolone antibacterial agents].
    Takahashi H; Hayakawa I; Akimoto T
    Yakushigaku Zasshi; 2003; 38(2):161-79. PubMed ID: 15143768
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparative in-vitro activity of quinolone carboxylic acids against Proteeae.
    Hawkey PM; Hawkey CA
    J Antimicrob Chemother; 1984 Nov; 14(5):485-9. PubMed ID: 6511707
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparative antimicrobial activity of enoxacin, ciprofloxacin, amifloxacin, norfloxacin and ofloxacin against 177 bacterial isolates.
    Bassey CM; Baltch AL; Smith RP
    J Antimicrob Chemother; 1986 May; 17(5):623-8. PubMed ID: 2941401
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The in-vitro activity of CI-934 compared with that of other new 4-quinolones and nalidixic acid.
    King A; Shannon K; Slegg J; Phillips I
    J Antimicrob Chemother; 1986 Aug; 18(2):163-9. PubMed ID: 3463557
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparative antibacterial activity of new quinolone-carboxylic acid derivatives.
    Mitsuhashi S
    Rev Infect Dis; 1988; 10 Suppl 1():S27-31. PubMed ID: 3347811
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Quinolones in vitro.
    Willems FT
    Pharm Weekbl Sci; 1986 Feb; 8(1):26-8. PubMed ID: 3960690
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Frequency and expression of mutational resistance to the 4-quinolone antibacterials.
    Smith JT
    Scand J Infect Dis Suppl; 1986; 49():115-23. PubMed ID: 3547618
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In-vitro assessment of lomefloxacin (SC-47111)--a new quinolone derivative.
    Finch R; Martin J; Pilkington R
    J Antimicrob Chemother; 1988 Dec; 22(6):881-4. PubMed ID: 3243735
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In vitro antibacterial activity of E-3604, a new 6-fluoroquinolone, on clinical isolates.
    Xicota MA; Coll R; Esteve M; Moros M; Parés J
    Drugs Exp Clin Res; 1987; 13(3):133-6. PubMed ID: 3622242
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The in-vitro activities of enoxacin and ofloxacin compared with that of ciprofloxacin.
    King A; Shannon K; Phillips I
    J Antimicrob Chemother; 1985 May; 15(5):551-8. PubMed ID: 3159712
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [In vitro effect of rosoxacin on hospital bacteria. Results of a multicenter study].
    Soussy CJ; Le Van Thoi J; Chanal M; Cluzel M; Fleurette J; Forey F; Thabaut A; Meyran M; Vandekerkove M; Sicard D; Acar JF; Kitzis MD; Veron M; Fauchere JL
    Pathol Biol (Paris); 1983 Jun; 31(6):504-8. PubMed ID: 6348657
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ciprofloxacin (BAY O 9867). Comparative in vitro activity study.
    Canton E; Garcia J; Vila B; Santos M; Gobernado M
    Microbiol Esp; 1984; 37(3-4):73-9. PubMed ID: 6242123
    [No Abstract]   [Full Text] [Related]  

  • 19. Laboratory evaluation of enoxacin: comparison with norfloxacin and nalidixic acid.
    Teoh-Chan CH; Cowlishaw A; Eley A; Slater G; Greenwood D
    J Antimicrob Chemother; 1985 Jan; 15(1):45-52. PubMed ID: 3156113
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of pH on the in vitro susceptibility of planktonic and biofilm-grown Proteus mirabilis to the quinolone antimicrobials.
    Irwin NJ; McCoy CP; Carson L
    J Appl Microbiol; 2013 Aug; 115(2):382-9. PubMed ID: 23647563
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.